Matrix Metalloproteinase 9 as Biomarker for Malignant Mammary Tumors in Dogs
Article Sidebar
Main Article Content
Abstract
Canine mammary tumors (CMTs) are frequently occurring types of tumor in female dogs. Matrix metallopeptidase 9 (MMP-9) plays a role in dismantling the extracellular matrix during normal bodily functions and diseases, including cancer. The goal of this research was to evaluate the serum levels of MMP-9 as a potential diagnostic indicator for CMTs using the ELISA method. We collected tissue samples from mammary glands and blood specimens from 50 dogs suspected of having CMTs and 30 healthy control dogs. Histological examination was used to diagnose the mammary tumors, with findings indicating that 88% of the cases were malignant CMT and 12% were benign. According to ELISA results, there was a statistically considerable elevation in the mean serum level of MMP-9 in malignant cases (199.09 ng/ml) compared to benign cases (56.721 ng/ml) and controls (36.055 ng/ml). MMP-9 serum levels were significantly correlated with dogs aged 10–15 years, as well as with female dogs. In terms of stage and grade of the disease, the mean levels of MMP-9 increased as the disease progressed (Stage IV: 343.235 ng/ml). However, there was no correlation with the grade of the disease, and in regard to MMP-9 serum levels, it was not feasible to distinguish between newly diagnosed cases and recurring cases. In conclusion, measuring serum MMP-9 levels may aid in assessing the presence of malignancies in dogs with mammary tumors.
Received: 27 March 2024
Revised: 12 May 2024
Accepted: 29 July 2024
Published: 28 December 2024
Downloads
Article Details
How to Cite
References
Burrai GP, Gabrieli A, Moccia V, Zappulli V, Porcellato I, Brachelente C. A statistical analysis of risk factors and biological behavior in canine mammary tumors: A multicenter study. Animals. 2020;10(9):1–12. https://doi.org/10.3390/ani10091687
Alabbody HHK, Lafta IJ. Incidence of Canine Digestive System Tumours in Baghdad Province. Iraqi J. Vet. Med. 2019;43(2):67–76. https://doi.org/10.30539/iraqijvm.v43i2.533
Lafta IJ, Kudhair BK, Iyiola OA, Ahmed EA, Chou T. Evaluating Expression of the STAG1 Gene as a Potential Breast Cancer Biomarker. Iraqi J. Vet. Med. 2021;45(2):7–13. https://doi.org/10.30539/ijvm.v45i2.1255
H Al-Kinani L, A Sharp M, M Wyatt K, Coiacetto F, R Sharp C, Rossi G. Haemoglobin Epsilon as a Biomarker for the Molecular Detection of Canine Lymphoma. Iraqi J. Vet. Med. 2023;47(1):21–7. https://doi.org/10.30539/ijvm.v 47i1.1494
Goldschmidt MH, Peña L, Rasotto R, Zappulli V. Classification and grading of canine mammary tumors. Vet Pathol. 2011;48(1):117–31. https://doi.org/10.1177 /0300985810393258
Sorenmo KU, Rasotto R, Zappulli V, Goldschmidt MH. Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms. Vet Pathol. 2011;48(1):85–97. https://doi.org/10.1177/0300985810389480
Saher M H. Study on bacterial isolation from dogs affected with malignant tumor. Iraqi J. Vet. Med. 2009;33(1):120–131. https://doi.org/10.30539/iraqijvm.v33i1.725
Santos AA, Lopes CC, Ribeiro JR, Martins LR, Santos JC, Amorim I F.Identification of prognostic factors in canine mammary malignant tumours: A multivariable survival study. BMC Vet Res. 2013;9:1–11. https://doi.org/10.1186/1746-6148-9-1
Ratajczak-Wielgomas K, Grzegrzolka J, Piotrowska A, Gomulkiewicz A, Witkiewicz W, Dziegiel P. Periostin expression in cancer-associated fibroblasts of invasive ductal breast carcinoma. Oncol Rep. 2016;36(5):2745–2754. https://doi.org/10.3892/or.2016.5095
Pula B, Jethon A, Piotrowska A, Gomulkiewicz A, Owczarek T, Calik J. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology. 2011;59(6):1249–1260. https://doi.org/10.1111/j.1365-2559.2011.04060.x
Pula B, Witkiewicz W, Dziegiel P, Podhorska-Okolow M. Significance of podoplanin expression in cancer-associated fibroblasts: A comprehensive review. Int J. Oncol. 2013;42(6):1849–1857. https://doi.org/10.3892/ijo.2013.1887
Morra L, Moch H. Periostin expression and epithelial-mesenchymal transition in cancer: A review and an update. Virchows Arch. 2011;459(5):465–475. https://doi.org/10.1007/s00428-011-1151-5
Hanifeh M, Rajamäki MM, Mäkitalo L, Syrjä P, Sankari S, Kilpinen S. Identification of matrix metalloproteinase-2 and -9 activities within intestinamucosa of clinically healthy beagle dogs. J. Vet. Med. Sci. 2014;76(8):1079–85. https://doi.org/10.1292/jvms.13-0578
Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562–73. https://doi.org/10.1016/j.cardi ores.2005.12.002
Khalil SI, Khalel EA, Sulaiman TI. Dense breast as a risk factor in breast malignancy. J. Fac Med. 2015;56(4):372–375. https://doi.org/10.32007/jfac medbagdad.564548
Mustafa S, Koran S, AlOmair L. Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects:A Review. Front Mol Biosci. 2022;9:1–10. https://doi.org/10.3389/fmolb.2022.896099
Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity.Nat Rev Immunol.2004;4(8):617–629. https://doi.org/10.1038/nri1418
Hassan HJ, Mohammad TU, Hameed EK. Assessment of serum metalloendopeptidase level in patients with double diabetes. Al-Kindy Col. Med. J. 2023;19(3):21–25. https://doi.org/10.47723/kcmj.v19i3.999
Aresu L, Giantin M, Morello E, Vascellari M, Castagnaro M, Lopparelli R.Matrix metalloproteinases and their inhibitors in canine mammary tumors. BMC Vet Res. 2011; 7:1-10. https://doi.org/10.1186/1746-6148-7-33
Fathipour V, Khaki Z, Nassiri SM. Evaluation of matrix metalloproteinases (MMP)-2 and MMP-9 activity in serum and biochemical and hematological parameters in spontaneous canine cutaneous tumors before and after surgical treatment. Vet Res Forum. 2018;9(1):19–26. https://pubmed.ncbi.nlm.nih.gov/29719660
Nowak M, Madej JA, Podhorska-Okolow M, Dziegiel P. Expression of extracellular matrix metalloproteinase (MMP-9), E-cadherin and proliferation-associated antigen Ki-67 and their reciprocal correlation in canine mammary adenocarcinomas. Vet Res Int. 2008;22(4):463–70. https://doi.org/10.1155/2012/357187
Al-Rubai’ee NS, Al-Rubai’ee NS. Fine needle aspiration cytology of breast lesions: Diagnostic values. J. Fac. Med Baghdad.2007; 48(4):413–5. https://doi.org/10.32007/jfacm edb agdad.4841468
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up. Histopathology. 1991;19(5):403-410. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x
Gundim LF, de Araújo CP, Blanca WT, Guimarães EC, Medeiros AA. Clinical staging in bitches with mammary tumors: Influence of type and histological grade. Can J Vet Res. 2016;80(4):318-322.27733787
Pastorinho, M Ramiro, Sousa, Ana Catarina A. Pets as Sentinels, Forecasters and Promoters of Human Health. Switzerland: Springer; 2020. Chapter 9, Canine and feline spontaneous mammary tumors as models of human breast cancer; P. (173-207). https://doi.org/10.1007/978-3-030-30734-9_9
Vascellari M, Baioni E, Ru G, Carminato A, Mutinelli F. Animal tumour registry of two provinces in northern Italy: incidence of spontaneous tumours in dogs and cats. BMC Vet Res. 2009;5(39):1–9. https://doi.org/10.1186/1746-6148-5-39
Sorenmo KU, Shofer FS, Goldschmidt MH. Effect of Spaying and Timing of Spaying on Survival of Dogs with Mammary Carcinoma. J Vet Intern Med. 2000;14(3):266. https://doi.org/10.1111/j.1939-1676.2000.tb01165.x
Ariyarathna H, de Silva N, Aberdein D, Kodikara D, Jayasinghe M, Adikari R. Clinicopathological diversity of Canine Mammary Gland Tumors in Sri Lanka: A one-year survey on cases presented to two veterinary practices. Vet Sci. 2018;5(2):46. https://doi.org/10.3390/vetsci5020046
Pastor N, Ezquerra LJ, Santella M, Caballé NC, Tarazona R, Durán ME. Prognostic significance of immunohistochemical markers and histological classification in malignant canine mammary tumours.Vet Comp Oncol. 2020;18(4):753–762. https://doi.org/10.1111/vco.12603
Restucci B, de Vico G, maiolino P. Evaluation of Angiogenesis in Canine Mammary Tumors by Quantitative Platelet Endothelial Cell Adhesion Molecule Immunohistochemistry. Vet Pathol. 2000; 37(4):297-301. https://doi.org/10. 1354/ vp.37-4-297
Pego ER, Fernández I, Núñez MJ. Molecular basis of the effect of MMP-9 on the prostate bone metastasis: A review. Urol Oncol Semin Orig Investig. 2018;36(6):272–282. http://dx.doi.org/10.1016/j.urolonc.2018.03.009
Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget. 2014;5(9):2736–2749. https://doi.org/10.18632%2Foncotarget.1932
Heintz L, Meyer-Schwesinger C. The intertwining of autophagy and the ubiquitin proteasome system in podocyte (patho)physiology. Cell Physiol Biochem. 2021;55(S4):68–95. https://doi.org/10.33594/00000043
Labrèche C, Cook DP, Abou-Hamad J, Pascoal J, Pryce BR, Al-Zahrani KN. Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGFβ/PI3K/AKT pathways. Breast Cancer Res. 2021;23(1):1–14. https://doi.org/10.1186/s13058-021-01487-8
Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–174. doi.10.1038/nrc745
Hojilla C V, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. B J Cancer. 2003;89(10):1817–1821. https://doi.org/10.1038/sj.bjc.6601327
Alrehaili AA, Gharib AF, Karam RA, Alhakami RA, El Sawy WH, Abd Elrahman TM. Clinical significance of plasma MMP‐2 and MMP‐9 levels as biomarkers for tumor expression in breast cancer patients in Egypt. Mol Biol Rep. 2020;47(2):1153–1160. https://doi.org/10.1007/s11033-019-05216-5
Heo DS, Choi H, Yeom MY, Song BJ, Oh SJ. Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients. Oncol Rep. 2014;31(4):1567–1572. https://doi.org/10.3892/or.2014.3001
Sung H, Choi JY, Lee SA, Lee KM, Han S, Jeon S. The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer. BMC Cancer. 2012;12. https://doi.org/10.1186/1471-2407-12-193
Blanco-Prieto S, Barcia-Castro L, Páez de la Cadena M, Rodríguez-Berrocal FJ, Vázquez-Iglesias L, Botana-Rial MI. Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis. BMC Cancer. 2017;17(1):1–8. https://doi.org/10.1186/s12885-017-3842-z
Zhang JY, Li Y, Wu JZ, Ye Z, Xu T, Ma R. Detection of serum VEGF and MMP-9 levels by luminex multiplexed assays in patients with breast infiltrative ductal carcinoma. Exp Ther Med. 2014;8(1):175–180. https://doi.org/10 .3892/etm. 2014.1685
Cai S, Zheng J, Song H, Wu H, Cai W. Relationship between serum TGF- β 1, MMP-9 and IL-1β and pathological features and prognosis in breast cancer. Front Genet. 2023;13:1–7. https://doi.org/10.3389/fgene.2022;1095338
Jiang H, Li H. Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021;21(1):1–13. https://doi.org/10.1186/s12885-021-07860-2
Mondal S, Adhikari N, Banerjee S, Amin SA, Jha T. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview. Eur J Med Chem. 2020;194:112260. https://doi.org/10.1016/j.ejmech.2020;112260
Mohammed Ali, Nidhal AK, Younis RM, Salai JS. Biomarkers for evaluating response to chemotherapy in metastatic breast cancer patients. J Fac Med Baghdad. 2017;59(2):132–137. https://doi.org/10.32007/jfacmedbagdad.592123